Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — Probiodrug — H1 2015 Earnings Presentation

40 slides from Vivoryon Therapeutics's earnings presentation, Aug 27, 2015

  1. Slide 1: Interim Report H1 2015

    Interim Report H1 2015 Reporting period January – June 2015 Halle (Saale), 27 August 2015 Konrad Glund Hendrik Liebers Inge Lues CEO CFO CDO

  2. Slide 2: Important notice and disclaimer

    Important notice and disclaimer This Presentation has been prepared and issued by Probiodrug AG (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any proj

  3. Slide 3: Content

    Content 1. Corporate introduction 2. Pipeline Update 3. Results January – June 2015 4. Outlook 5. Q & A 3

  4. Slide 4: Key Highlights January to June 2015

    Key Highlights January to June 2015  Phase 2a study of novel treatment for Alzheimer’s disease, the SAPHIR trial, initiated  Additional data on Glutaminyl Cyclases (QCs) in Alzheimer’s disease published in Acta Neuropathologica  Data on Probiodrug’s Anti-pGlu-3 Abeta monoclonal antibody presented

  5. Slide 5: Alzheimer's disease: growing burden, no cure

    Alzheimer's disease: growing burden, no cure Worldwide patient population will triple in Alzheimer's disease introduction* the next 30 years**  Leading cause of dementia, ultimately CAGR +2% 135 leading to death  Large burden on families 44  Growing cost for society  Available treatments margina

  6. Slide 6: Investment highlights

    Investment highlights  Alzheimer’s disease (“AD”) is a devastating neurological disease affecting 1 Alzheimer’s disease: major burden, no cure  over 44 million people world-wide* No cure or long-term beneficial treatment available  No new drugs approved since 2007**  After years of “drought” ris

  7. Slide 7: Experienced management team

    Experienced management team Management team Biography Konrad Glund,  Co-founder of Probiodrug, CEO since 2006 PhD, CEO  Led development of DP 4 inhibitors, transactions with Merck, Novartis, OSI and Ferring Co-founder  COO & VP business development OSI (Prosidion) in 2004-2006 Chairman of the  >

  8. Slide 8: Original Abeta approach

    Original Abeta approach Probiodrug targets toxic structures in Alzheimer's disease Considerations  Most new drug Most new drugs have focused on Abeta formation or Abeta/plaque clearance treatments have targeted Abeta or plaques  Therapies have focused on: 1. Reduction of Abeta formation 2. Clearan

  9. Slide 9: Probiodrug's differentiated approach

    Probiodrug’s differentiated approach Probiodrug targets toxic structures in Alzheimer's disease Considerations  Probiodrug and others Most new drugs have focused on Abeta formation or Abeta/plaque clearance have progressed insights on Abeta and its role in AD  Abeta has a physiological function 

  10. Slide 10: "Prevent formation" concept

    “Prevent formation” concept Mechanism: QC (Glutaminyl Cyclase) is crucial for QC QC pGlu-Abeta formation enzyme enzyme Abeta pGlu-Abeta Abeta “Toxic Trigger” QC enzyme is crucial for pGlu-Abeta Inhibiting QC, no pGlu-Abeta formation Therapeutic effect: Aim to prevent formation of toxic “pre-plaques”

  11. Slide 11: "Capture and Clear" concept

    “Capture and Clear” concept Toxic “pre-plaques” and plaques 1 containing pGlu-Abeta Antibody to capture and clear 2 existing pGlu-Abeta Reduced number of toxic oligomers 3 of Abeta 11

  12. Slide 12: Extensive evidence for differentiated approach

    Extensive evidence for differentiated approach Publications (selection) Core data  pGlu-Abeta is specific for AD  pGlu-Abeta and oligomers correlate with disease progression  QC is crucial for pGlu- Abeta production  QC overexpression drives pGlu-Abeta and AD pathology Source: Schilling et al. G

  13. Slide 13: pGlu-Abeta appears in brains of AD patients only

    pGlu-Abeta appears in brains of AD patients only Appearance of pGlu-Abeta in AD brains pGlu-Abeta level versus MMSE in brain r2 -0.8867 pGlu-Abeta Total Abeta P value 0.0001 mAb Abeta3(pE) mAb4G8 30 MMSE Score 20 10 Normal 0 0 100 200 300 400 500 600 pGlu-Abeta (ng/g tissue) MORAWSKI M, Schilling S

  14. Slide 14: Probiodrug demonstrated toxic role of Abeta oligomers in AD

    Probiodrug demonstrated toxic role of Abeta oligomers in AD Toxic role of pGlu-Abeta and oligomers 100% Abeta 100% pGlu- 5% pGlu-Abeta Vehicle 95% Abeta (full length) Abeta (full length) Wild Type Neurons Cell viability analysis (XTT plate reader assay) on Primary Mouse Neurons after various peptide

  15. Slide 15: pGluAβ - N-modified Aβ - abundant in AD brain

    pGluAβ - N-modified Aβ - abundant in AD brain Amyloid Precursor Protein Aβ1 Aβ11 Aβ40 Aβ42 Human plaques contain DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT significant amounts of N-truncated and Masters, CL et al. PNAS 1985 modified Aβ-peptides „ragged peptides“ Mori, H et al. JBC 1992 25% of Aβ is

  16. Slide 16: pGlu-Abeta is formed by Glutaminyl Cyclase

    peptide pGlu-Abeta is formed NH by Glutaminyl Cyclase peptide (QC) NH H2N O - NH3 H N O QC cyclases N-terminal Glutamate O O NH2 peptide NH peptide H2N NH O - H2O H N O O slow, O OH QC-catalyzed only Glutamate (Glu, E) Pyroglutamate (pGlu, pE)  Probiodrug scientists were the first to discover the r

  17. Slide 17: QC overexpression drives to disease development

    QC overexpression drives to disease development Elevated QC expression Increased pGlu-Abeta Abeta oligomers lead to Neuronal dysfunction results increases pGlu-Abeta enhances oligomer formation synapse loss in brain in memory deficits pGlu-Abeta levels in normal AD vs QC-AD Abeta Oligomers presence

  18. Slide 18: AD is a synaptic failure

    AD is a synaptic failure* Oligomers impact synapses pGlu-Aβ triggers formation of APP neurotoxic sAβos from pGlu-Aβ and normal Aβ Production Synaptic QC impairment Tau pathology Cognitive deficits Aβ pGlu-Aβ Oligomers Neuronal death Amyloid plaque Cognitive decline deposition/ pGlu-Aβ is inflammatio

  19. Slide 19: QC-Inhibition improves Network Function

    QC-Inhibition improves Network Function  Electrical activity of pyramidal cells breaks down long before cell death occurs.  shown in a tg mouse model single cell resolution mapping of neuronal thallium  This specific disruption of normal cross- laminar cortical processing coincided with a decline

  20. Slide 20: PQ912: efficacy in pre-clinical AD model

    PQ912: efficacy in pre-clinical AD model Preventive Therapeutic Start+: 3 months 7.5 months 8 months Duration: 6 months 0.75 - 1.5 months 4 months Soluble (TBS) Insoluble Soluble (TBS) Insoluble Soluble (TBS) Insoluble 10 10 pE-A(3-42) [ng/g] pGlu-Abeta [pg/g] pGlu-Abeta [pg/g] pGlu-Abeta [pg/g] 5

  21. Slide 21: Biogen's Aducanumab shows strong data targeting aggregated Abeta

    Biogen’s Aducanumab (BIIB037) shows strong data targeting aggregated Abeta, including soluble oligomers Biogen’s Aducanumab is a high affinity antibody against specific Abeta targets  Aducanumab’s differs from other antibodies in development for AD, such as crenezumab and gantenerumab, due to high

  22. Slide 22: Content

    Content 1. Corporate introduction 2. Pipeline Update 3. Results January – June 2015 4. Outlook 5. Q & A 22

  23. Slide 23: Focused proprietary pipeline

    Focused proprietary pipeline Pre- Product Phase 1 Phase 2 clinical PQ912  Small molecule QC inhibitor First patient enrolled March 2015 PBD-C06  pGlu-Abeta specific monoclonal antibody PQ1565  Small molecule QC inhibitor Clinical proof of concept 23

  24. Slide 24: PQ912: the first QC inhibitor against AD in the clinic

    PQ912: the first QC inhibitor against AD in the clinic Phase 1 results Ongoing  PQ912 was tested in a phase 1 clinical study on  2015 / 2016 phase 2a clinical 200 young and elderly volunteers trial (SAPHIR)  Safe and well tolerated, maximum tolerated dose  Considerations not reached  Acute cogn

  25. Slide 25: Ongoing SAPHIR Phase 2a trial in early AD patients

    Ongoing SAPHIR Phase 2a trial in early AD patients for safety and early efficacy SAPHIR Phase 2a trial design Objectives and read-outs  Primary objective: To assess safety and  Trial ongoing tolerability of PQ912 compared with placebo  Six European countries  First patient enrolled March 2015 

  26. Slide 26: pGlu-Abeta approach

    pGlu-Abeta approach Right measures Right target  Variety of readouts  Strong pre-clinical validation • Cognitive tests • pGlu-Abeta is critical for amyloid • Neuronal oligomer and plaque formation, connectivity via Right marker causing cognitive decline EEG and fMRI Potential biomarkers • Distinct

  27. Slide 27: PBD-C06: a selective antibody targeting pGlu-Abeta

    PBD-C06: a selective antibody targeting pGlu-Abeta Pre-clinical evidence Update  Recognizes pGlu-Abeta with very high  Important next step by selecting a selectivity and affinity to multiple forms suitable IgG variant as development candidate taken  Promising studies performed in Alzheimer’s mous

  28. Slide 28: Lilly's pGlu-Abeta antibody data outlines rationale for combination therapy

    Lilly’s pGlu-Abeta antibody data outlines rationale for combination therapy Background: Eli Lilly has a pGlu-Abeta specific Antibody in Phase 1  In May 2013, Lilly started a phase 1 study in 100 people on the spectrum of mild cognitive impairment due to AD or mild AD in the United States and Japan

  29. Slide 29: PBD-C06: Capture and Clear

    PBD-C06: “Capture and Clear” PBD-C06 reduces pGlu-Abeta PBD-C06 reduces total Abeta % ROI (normalized to PBS) % ROI (normalized to PBS) Control Post PBD-C06 treatment PBD-C06 PBD-C06 Control Control Hippocampal brain section of AD- pGlu-Abeta is reduced by 60% Total Abeta is reduced by 40% post like

  30. Slide 30: Content

    Content 1. Corporate introduction 2. Pipeline Update 3. Results January – June 2015 4. Outlook 5. Q & A 30

  31. Slide 31: Key Highlights January to June 2015

    Key Highlights January to June 2015  Phase 2a study of novel treatment for Alzheimer’s disease, the SAPHIR trial, initiated  Additional data on Glutaminyl Cyclases (QCs) in Alzheimer’s disease published in Acta Neuropathologica  Data on Probiodrug`s Anti-pGlu-3 Abeta monoclonal antibody presented

  32. Slide 32: Annual General Meeting 2015 (AGM 2015)

    Annual General Meeting 2015 (AGM 2015) On 10 June 2015, Probiodrug held its AGM 2015. All resolutions proposed were approved at the meeting including:  Adoption of the annual financial statements and the management report of Probiodrug AG for the financial year 2014  Ratification of the actions of

  33. Slide 33: Key financial figures January – June 2015 (according to IFRS)

    Key financial figures January – June 2015 (according to IFRS) Jan – Jun 2015 Jan – Jun 2014 Jan – Dec 2014 (unconsolidated*) (unconsolidated*) In EUR k Earnings, Financial and Net Assets Position Revenues 0 0 0 Operating profit/loss -6,177 -3,738 -11,267 Net loss for the period -6,233 -3,761 -11,437

  34. Slide 34: Details of the Financial Results January – June 2015

    Details of the Financial Results January – June 2015 (according to IFRS) Net loss net loss  Net loss in line with expectations  Operating loss primarily driven by R&D expenses, in particular the SAPHIR study  Increase in operating expenses reflects operating loss EUR 6,177k primarily administrati

  35. Slide 35: Content

    Content 1. Corporate introduction 2. Pipeline Update 3. Results 2014 4. Outlook 5. Q & A 35

  36. Slide 36: Outlook 2015

    Outlook 2015 The mid-term focus of Probiodrug’s business activities can be summarised as follows:  Further preclinical and clinical testing of the development candidate PQ912, in particular execution of the first patient study in a Phase 2a trial in 2015/ 2016 and the evaluation and design of a lon

  37. Slide 37: Anticipated news flow (selection)

    Anticipated news flow (selection)  PQ912 CTA submission for phase 2 ✔ 2014  PQ912 First patient enrolled ✔  PQ912 Publication of complete phase 1 results 2015  PBD-C06 Results in inflammatory part of AD pathology in animal model  PQ912 Assessment of potential in Down syndrome  PBD-C06 start of

  38. Slide 38: Financial Calendar

    Financial Calendar May 13th, 2015 Interim Management Statement Q1 2015 June 10th, 2015 Annual General Meeting of Shareholders in Berlin August 27th, 2015 Interim Report, half year results 2015 November 19th, 2015 Interim Management Statement Q3 2015 38

  39. Slide 39: Content

    Content 1. Corporate introduction 2. Pipeline Update 3. Results 2014 4. Outlook 5. Q & A 39

  40. Slide 40: Q&A

    probtodrug O&A probtodrug

Probiodrug — H1 2015 Earnings Presentation on 6ix